Needham & Company LLC Reiterates Buy Rating for Revolution Medicines (NASDAQ:RVMD)

Revolution Medicines (NASDAQ:RVMD – Get Free Report)‘s stock had its “buy” rating reissued by Needham & Company LLC in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $36.00 target price on the stock. Needham & Company LLC’s target price would indicate a potential upside of 9.12% from […]

Related Keywords

United States ,Hong Kong ,America ,Jeff Cislini ,Raymond James ,Piper Sandler ,Margareta Horn ,Revolution Medicines Company Profile ,Shell Asset Management Co ,Manchester Capital Management ,Needham Company ,Us Bancorp ,Hong Kong Ltd ,Revolution Medicines Inc ,Securities Exchange Commission ,Revolution Medicines ,Get Free Report ,General Counsel Jeff Cislini ,Exchange Commission ,Asset Management ,Kong Ltd ,Revolution Medicines Daily ,Nasdaq Rvmd ,Rvmd ,Medical ,Reiterated Rating ,Needham Company Llc ,